Skip to content

Study · Randomized controlled trial · n = 68 · 2024

7 results

Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.

Dejgaard TF, Frandsen CS, Kielgast U, Størling J, Overgaard AJ, Svane MS, Olsen MH, Thorsteinsson B, Andersen HU, Krarup T, Holst JJ, Madsbad S

Diabetes, obesity & metabolism27 Aug 2024Cited by 24 (Europe PMC)

PMID39192527 (opens in a new tab)DOI10.1111/dom.15889 (opens in a new tab)PepBankPUB-39192527
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 1 diabetes, the 4-hour C-peptide AUC response was maintained with liraglutide but decreased with placebo after 52 weeks.

    In plain wordsIn adults with newly diagnosed type 1 diabetes, insulin-making function held steady on liraglutide but fell on placebo over 52 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseC-peptide AUC at week 52
    Study

    n = 68

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.8 mg once daily · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    After 52 weeks, the 4-hour AUC C-peptide response was maintained with liraglutide, but decreased with placebo (P = .002).
    1 context sentence
    Summary · context
    In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 1 diabetes, C-peptide AUCs were similar for liraglutide and placebo 6 weeks after treatment ended.

    In plain wordsIn adults with newly diagnosed type 1 diabetes, insulin-making function was similar with liraglutide and placebo 6 weeks after treatment stopped.

    Peptide
    Liraglutide
    Outcome
    No significant changeC-peptide AUC 6 weeks after end of treatment
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.8 mg once daily · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Six weeks after end-of-treatment, C-peptide AUCs were similar for liraglutide and placebo.
    1 context sentence
    Summary · context
    In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 1 diabetes, the required daily insulin dose fell with liraglutide but rose with placebo at week 52.

    In plain wordsIn adults with newly diagnosed type 1 diabetes, daily insulin needs fell on liraglutide but rose on placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal daily insulin dose
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.8 mg once daily · 52 weeksAs given in this study (human).

    Measurements

    Daily insulin dose
    0.3 units/kg/day
    liraglutide, baseline
    Daily insulin dose
    0.23 units/kg/day
    liraglutide, week 52
    Daily insulin dose
    0.29 units/kg/day
    placebo, baseline
    Daily insulin dose
    0.43 units/kg/day
    placebo, week 52

    Source sentences

    Summary
    The average required total daily insulin dose decreased from 0.30 to 0.23 units/kg/day with liraglutide, but increased from 0.29 to 0.43 units/kg/day in the placebo group at week 52 (P < .001).
    1 context sentence
    Summary · context
    In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 1 diabetes, 13 patients on liraglutide versus two on placebo had a period without the need for insulin.

    In plain wordsIn adults with newly diagnosed type 1 diabetes, more patients on liraglutide (13) than on placebo (two) had a time without needing insulin.

    Peptide
    Liraglutide
    Outcome
    IncreasePatients with time without insulin treatment
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.8 mg once daily · 52 weeksAs given in this study (human).

    Measurements

    Patients with insulin-free time
    13 patients
    liraglutide
    Patients with insulin-free time
    2 patients
    placebo

    Source sentences

    Summary
    Time without the need for insulin treatment was observed in 13 versus two patients and lasted for 22 weeks (from 3 to 52 weeks) versus 6 weeks (from 4 to 8 weeks) on average for liraglutide and placebo, respectively.
    1 context sentence
    Summary · context
    In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 1 diabetes, the time without insulin treatment lasted 22 weeks on average with liraglutide versus 6 weeks with placebo.

    In plain wordsIn adults with newly diagnosed type 1 diabetes, the insulin-free period lasted about 22 weeks on liraglutide and 6 weeks on placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseDuration of time without insulin treatment
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.8 mg once daily · 52 weeksAs given in this study (human).

    Measurements

    Average insulin-free duration
    22 weeks
    liraglutide
    Average insulin-free duration
    6 weeks
    placebo

    Source sentences

    Summary
    Time without the need for insulin treatment was observed in 13 versus two patients and lasted for 22 weeks (from 3 to 52 weeks) versus 6 weeks (from 4 to 8 weeks) on average for liraglutide and placebo, respectively.
    1 context sentence
    Summary · context
    In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment.
  6. 06HumanRandomized controlled trialSafety outcome

    In adults with newly diagnosed type 1 diabetes, patients on liraglutide had fewer hypoglycaemia episodes than patients on placebo.

    In plain wordsIn adults with newly diagnosed type 1 diabetes, liraglutide users had fewer low blood sugar episodes than placebo users.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia episodes
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    1.8 mg once daily · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide had fewer episodes of hypoglycaemia compared with placebo-treated patients.
    1 context sentence
    Summary · context
    In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment.
  7. 07HumanRandomized controlled trialSafety outcome

    In adults with newly diagnosed type 1 diabetes, the adverse events with liraglutide were predominantly gastrointestinal and transient.

    In plain wordsIn adults with newly diagnosed type 1 diabetes, side effects of liraglutide were mostly stomach and gut related and short-lived.

    Peptide
    Liraglutide
    Outcome
    Not applicableAdverse events with liraglutide
    Study

    n = 68

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.8 mg once daily · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The adverse events with liraglutide were predominantly gastrointestinal and transient.
    1 context sentence
    Summary · context
    In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.